The role of interleukin-1 (IL-1) has been studied in many diseases, ranging from auto-inflammatory diseases to malignancies, and much has been discovered. There are currently four IL-1 inhibitors available, but only two have been approved in Europe: the receptor antagonist anakinra, and the IL-1b selective inhibitor canakinumab. The aim of this paper is to summarize the on- and off-label use of canakinumab (ILARIS).
To cite this article
The journey of canakinumab; on- and off-label indications
Beyond Rheumatology 2019;
1 (1): e256
Published online: 06 May 2019
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.